Articles with public access mandates - Richard D. CarvajalLearn more
Not available anywhere: 4
Prognosis of acral melanoma: a series of 281 patients
DM Bello, JF Chou, KS Panageas, MS Brady, DG Coit, RD Carvajal, ...
Annals of surgical oncology 20, 3618-3625, 2013
Mandates: US National Institutes of Health
Genomic profiling of metastatic uveal melanoma and clinical results of a phase I study of the protein kinase C inhibitor AEB071
S Piperno-Neumann, J Larkin, RD Carvajal, JJ Luke, GK Schwartz, ...
Molecular cancer therapeutics 19 (4), 1031-1039, 2020
Mandates: National Institute for Health Research, UK
Safety and tolerability of MEDI0562, an OX40 agonist mAb, in combination with durvalumab or tremelimumab in adult patients with advanced solid tumors
JW Goldman, SA Piha-Paul, B Curti, KS Pedersen, TM Bauer, ...
Clinical Cancer Research 28 (17), 3709-3719, 2022
Mandates: US National Institutes of Health
Surveillance for early detection of metastatic ocular melanoma following definitive local therapy
JH Francis, T Kivelä, RD Carvajal
Future Medicine Ltd, 2014
Mandates: US National Institutes of Health
Available somewhere: 120
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ...
New England Journal of Medicine 366 (26), 2443-2454, 2012
Mandates: US National Institutes of Health
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ...
Journal of clinical oncology 32 (10), 1020-1030, 2014
Mandates: US National Institutes of Health
Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer
SN Gettinger, L Horn, L Gandhi, DR Spigel, SJ Antonia, NA Rizvi, ...
Journal of clinical oncology 33 (18), 2004-2012, 2015
Mandates: US National Institutes of Health
Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at …
TZ Horvat, NG Adel, TO Dang, P Momtaz, MA Postow, MK Callahan, ...
Journal of Clinical Oncology 33 (28), 3193-3198, 2015
Mandates: US National Institutes of Health
KIT as a therapeutic target in metastatic melanoma
RD Carvajal, CR Antonescu, JD Wolchok, PB Chapman, RA Roman, ...
Jama 305 (22), 2327-2334, 2011
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Uveal melanoma
MJ Jager, CL Shields, CM Cebulla, MH Abdel-Rahman, HE Grossniklaus, ...
Nature reviews Disease primers 6 (1), 24, 2020
Mandates: European Commission
Overall survival benefit with tebentafusp in metastatic uveal melanoma
P Nathan, JC Hassel, P Rutkowski, JF Baurain, MO Butler, M Schlaak, ...
New England Journal of Medicine 385 (13), 1196-1206, 2021
Mandates: US National Institutes of Health
Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab
SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ...
JAMA oncology 5 (10), 1411-1420, 2019
Mandates: US National Institutes of Health
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival
GY Ku, J Yuan, DB Page, SEA Schroeder, KS Panageas, RD Carvajal, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2010
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial
RD Carvajal, JA Sosman, JF Quevedo, MM Milhem, AM Joshua, ...
Jama 311 (23), 2397-2405, 2014
Mandates: US National Institutes of Health
Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab
DF McDermott, CG Drake, M Sznol, TK Choueiri, JD Powderly, DC Smith, ...
Journal of clinical oncology 33 (18), 2013-2020, 2015
Mandates: US National Institutes of Health
Alterations of immune response of non-small cell lung cancer with azacytidine
J Wrangle, W Wang, A Koch, H Easwaran, HP Mohammad, F Vendetti, ...
Oncotarget 4 (11), 2067, 2013
Mandates: US National Institutes of Health
Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205
MV Dhodapkar, M Sznol, B Zhao, D Wang, RD Carvajal, ML Keohan, ...
Science translational medicine 6 (232), 232ra51-232ra51, 2014
Mandates: US National Institutes of Health
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies
AP Algazi, KK Tsai, AN Shoushtari, RR Munhoz, Z Eroglu, JM Piulats, ...
Cancer 122 (21), 3344-3353, 2016
Mandates: US National Institutes of Health
Treatment of uveal melanoma: where are we now?
J Yang, DK Manson, BP Marr, RD Carvajal
Therapeutic advances in medical oncology 10, 1758834018757175, 2018
Mandates: US National Institutes of Health
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
SP D’Angelo, AN Shoushtari, NP Agaram, D Kuk, LX Qin, RD Carvajal, ...
Human pathology 46 (3), 357-365, 2015
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program